Combination treatment for advanced bile duct cancer
Part of Cancer clinical trials.
This study tests a combination of two drugs (surufatinib and toripalimab) plus a chemo infusion directly into the liver (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that cannot be removed by surgery or has spread, and you have not had systemic treatment for it (or it came back more than 6 months after chemo).
- You are between 18 and 75 years old.
- You are generally able to do daily activities (ECOG score 0-1) and expected to live at least 3 months.
- Your liver function is good (Child-Pugh grade A) and your blood counts, liver, and kidney tests are within certain limits.
- You have at least one tumor that can be measured on a scan (at least 1 cm).
- You have not had certain other cancers, brain metastases, or serious heart or bleeding problems.
- You are not pregnant or breastfeeding, and if you could have children, you agree to use effective birth control during and 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests a combination of drugs to treat advanced bile duct cancer that cannot be removed by surgery. The treatment may help shrink tumors and improve outcomes.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.